CCR2 and metabolic dysfunction-associated steatotic liver disease: Genetic deletion and pharmacologic inhibition of CCR2 in mouse models of NAFLD/NASH led to recruitment of fewer monocytes and improved liver pathology (Weisberg et al., 2006; Yang et al., 2009; Baeck et al., 2012; Miura et al., 2012).